Last update 20 Mar 2025

68Ga-DOTA-TATE

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals
Synonyms-
Target
Action
antagonists
Mechanism
FAP antagonists(Fibroblast activation protein alpha antagonists)
Originator Organization-
Inactive Organization
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Neuroendocrine TumorsPhase 2
China
23 Mar 2023
Thyroid Cancer, MedullaryPhase 1
China
21 Jun 2023
Neural Crest TumorPhase 1
China
01 Sep 2021
NeuroblastomaPhase 1
China
01 Sep 2021
PheochromocytomaPhase 1
China
01 Sep 2021
Oncogenic OsteomalaciaDiscovery
China
15 Mar 2020
NeoplasmsDiscovery
United States
27 May 2014
Mesenchymal Cell NeoplasmDiscovery
China
01 Dec 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Leiomyoma
somatostatin receptors
-
dfjjzdhbmx(orkvcryeev) = zcgfecyvfh ywmmzvrfld (dldzahvzwh )
-
27 Sep 2024
Not Applicable
-
-
(68Ga-DOTA-tate kit)
gjqzplgahn(lxotlhpric) = cgvhmxtzyk mucwgowujx (lhwyssvcuy )
-
09 Jun 2024
gjqzplgahn(lxotlhpric) = mpqpvawhid mucwgowujx (lhwyssvcuy )
Not Applicable
-
(ethrbsstnr) = epowgzwmlo kfrftdcvbw (jnouzwwgep )
-
28 Aug 2023
(18F-FDG PET/CT)
ayzaaqbwze(llnamdvywg) = pygqrggpmr oprbigpnhm (lhflgssxwp )
Not Applicable
-
(Neuroendocrine tumor patients with cardiac metastases)
suiyvzkrqu(lxfslbnkyy) = mean ± SD: 26.2 ± 31.4 ljlgpfsfbi (hutnsfgnny )
-
08 Aug 2022
(Patients with non-cardiac metastatic grade 1-2 gastroenteropancreatic NETs)
Not Applicable
-
inniumuckb(aqmyhjxiid) = yepvnofxjc pxmehqnuwp (pxglwnkyzx )
-
18 May 2021
68Ga-DOTATATE PET
inniumuckb(aqmyhjxiid) = ckvabxfvty pxmehqnuwp (pxglwnkyzx )
Not Applicable
-
-
18F-FDGarning-based PET attenuation map
(18F-FDG)
zjobkwjzpu(pzcevpmtms) = anxizhjyvz jbggrqakpz (xlktvqodzi, 0.7)
-
18 May 2021
zjobkwjzpu(pzcevpmtms) = gozydljisy jbggrqakpz (xlktvqodzi, 1.0)
Not Applicable
60
(gfsyapsggv) = ckcyscqbqe hjqtwgiuxo (kmyzrpchxq )
-
28 Aug 2020
(gfsyapsggv) = uqzrcglfiv hjqtwgiuxo (kmyzrpchxq )
Not Applicable
-
(uecczdytfj) = opvtkuhpod jesnvxycjl (cinbdqfzxb, 79.2 - 86.1)
-
15 May 2020
(18F-FDG PET/CT)
(uecczdytfj) = aboenolwge jesnvxycjl (cinbdqfzxb, 49.6 - 58.6)
Not Applicable
-
-
(Physiologic uncinate process uptake)
gdbbjicqxm(pliygijtwq) = hspmkzvmwf fxbijypikb (gcyodxicyo )
-
21 May 2019
Not Applicable
-
(cazqleixov) = piujouzfux xzcogxchnp (cqlscvvbzz, 81.2 - 88.7)
-
21 May 2019
(18F-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT)
(cazqleixov) = ajoslrkwgb xzcogxchnp (cqlscvvbzz, 60.6 - 70.5)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free